receptor | LDL receptor | Receptor (biochemistry) | Continuous erythropoietin receptor activator | GABA receptor | Epidermal growth factor receptor | NMDA receptor | Sensory receptor | receptor (biochemistry) | metabotropic glutamate receptor | GABA transaminase | 5-HT2A receptor | VLDL receptor | TGF beta receptor 2 | receptor antagonist | epidermal growth factor receptor | 5-HT receptor | RAR-related orphan receptor alpha | Metabotropic glutamate receptor 5 | Metabotropic glutamate receptor 2 | G protein-coupled receptor | AMPA receptor | Adenosine A1 receptor | Toll-like receptor | TNF receptor associated periodic syndrome | taste receptor | Sigma-1 receptor | Receptor antagonist | Receptor activity-modifying protein | Pancreatic polypeptide receptor 1 |
Published in the April 2007 issue of Nature Neuroscience, their brief communication outlined an experiment designed to test the underlying theory proposed to explain the purported efficacy of declarative memory deficits associated with the mouse model of human Down Syndrome.
Ro4938581 is a nootropic drug invented in 2009 by a team working for Hoffmann-La Roche, which acts as a subtype-selective inverse agonist at the benzodiazepine binding site on the receptor.